Sugi Predict

Sugi Predict / Compounds / SCHEMBL20074656

SCHEMBL20074656

SCHEMBL20074656

COC(=O)c1ccnc2ccc(Br)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ TSHR P16473 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ NR4A2 P43354 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ SLC22A12 Q96S37 5/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ GAK O14976 1/20 0.47
▸ EPHB6 O15197 1/20 0.47
▸ RIPK2 O43353 1/20 0.47
▸ STK16 O75716 1/20 0.47
▸ ABL1 P00519 1/20 0.47
▸ ACVR1 Q04771 1/20 0.47
▸ AAK1 Q2M2I8 1/20 0.47
▸ COQ8A Q8NI60 1/20 0.47
▸ NLK Q9UBE8 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PSMD14 O00487 1/20 0.46
▸ GAA P10253 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680913 1.00 L3MBTL1 (0.62) L3MBTL1TSHRHTTNR4A2LMNA
Hydrochloric Acid SCHEMBL29681190 0.98 L3MBTL1 (0.60) L3MBTL1TSHRHTTNR4A2LMNA
Hydrochloric Acid SCHEMBL29090984 0.98 L3MBTL1 (0.60) L3MBTL1TSHRHTTNR4A2LMNA
SCHEMBL30717956 0.88 L3MBTL1 (0.51) L3MBTL1TSHRHTTNR4A2LMNA
SCHEMBL1998421 0.88 L3MBTL1 (0.51) L3MBTL1TSHRHTTNR4A2LMNA
SCHEMBL7365268 0.84 ALDH1A1 (0.66) L3MBTL1TSHRHTTLMNASLC22A12
SCHEMBL21247101 0.84 TSHR (0.46) L3MBTL1TSHRHTTLMNASLC22A12
SCHEMBL31510551 0.84 ALDH1A1 (0.66) L3MBTL1TSHRHTTLMNASLC22A12
SCHEMBL24728976 0.83 LMNA (0.52) L3MBTL1TSHRHTTLMNAKDM4E
SCHEMBL22492429 0.83 LMNA (0.52) L3MBTL1HTTNR4A2LMNASLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543869-B1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2026-05-27 — — EP disclosed
WO-2026098607-A1 F-18 LABELED AQUEOUS PHARMACEUTICAL COMPOSITION TARGETING LIGAND OF FIBROBLAST ACTIVATION PROTEIN, AND PREPARATION METHOD THEREFOR 天津恒瑞医药有限公司 2026-05-15 — — WO disclosed
US-20260070899-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2026-03-12 — — US disclosed
EP-4562000-A1 AMINOHETEROARYL KINASE INHIBITORS Allorion Therapeutics Inc (US) 2025-06-04 — — EP disclosed
WO-2025106939-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
WO-2025106926-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
EP-4543878-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES Astrazeneca AB (SE) 2025-04-30 — — EP disclosed
EP-4543869-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES Astrazeneca AB (SE) 2025-04-30 — — EP disclosed
CN-119630652-A Amino heteroaryl kinase inhibitors 安锐生物医药公司 2025-03-14 — — CN disclosed
CN-119562951-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2025-03-04 — — CN disclosed
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-10-05 — — US disclosed
CN-116745291-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2023-09-12 — — CN disclosed
WO-2023161879-A1 CYTOTOXICITY TARGETING CHIMERAS FOR FIBROBLAST ACTIVATION PROTEIN-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 — — WO disclosed
WO-2022149057-A1 CDK INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2022-07-14 — — WO disclosed
WO-2022130270-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2022-06-23 — — WO disclosed
WO-2022130270-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2022-06-23 — — WO disclosed
CN-112023064-A Tin-based derivative of fibroblast activation protein inhibitor for labeling nuclide 211At and preparation method and application thereof 南京大为科创服务有限责任公司 2020-12-04 — — CN disclosed
CN-111511731-A Olefin compounds as farnesoid X receptor modulators 百时美施贵宝公司 2020-08-07 — — CN disclosed
EP-3527570-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2019-08-21 — — EP disclosed
WO-2018068759-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2018-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070899-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES FAP, CTRL, CTSC L3MBTL1 4160/4885TSHR 1550/4885HTT 1307/4885
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES FAP, PREP, CTRL L3MBTL1 4334/4885TSHR 1989/4885HTT 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.